Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 324353

Sort by

Sort Order Select

Journal Articles

Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia

William G. Wierda, Barbara F. Eichhorst, Michael J Hallek

Blood blood.2025028570.

https://doi.org/10.1182/blood.2025028570

Published: 2025

Journal Articles

Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers

Anna-Karina Felder, Sjoerd J.D. Tjalsma, Han J.M.P. Verhagen, Rezin Majied, Marjon J.A.M. Verstegen, Thijs C.J. Verheul, Jeffrey van Haren, Rebecca Mohnani, Richard Gremmen, Peter H.L. Krijger, Sjaak Philipsen, Emile van den Akker, Wouter de Laat

Blood blood.2024028128.

https://doi.org/10.1182/blood.2024028128

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies

Blood blood.2025028387.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Nora M. Gibson, Eugene Khandros, Caitlin W. Elgarten, Elizabeth Worster, Dimitrios S. Monos, Alexis A. Thompson, Janet L. Kwiatkowski, Timothy S. Olson

Blood (2025) 145 (22): 2666–2670.

https://doi.org/10.1182/blood.2024027034

Published: 2025

Includes: Supplemental data

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them

Ainsley V. C. Knox, Lauren Y. Cominsky, Di Sun, Emylette Cruz Cabrera, Brian E. Nolan, Edann Ofray, Elisa Benetti, Camilla Visconti, Federica Barzaghi, Sergio D. Rosenzweig, Monica G. Lawrence, Kathleen E. Sullivan, Samuel Yoon, Suzanna Rachimi, Nurcicek Padem, Erin Conboy, Maja Stojanovic, Gordana Petrovic, Srdjan Pasic, Joseph Church, Ronald M. Ferdman, Fabio Candotti, Tiphaine Arlabosse, Katerina Theodoropoulou, Cullen M. Dutmer, László Maródi, Gabriella Szücs, Arnon Broides, Amit Nahum, Jacov Levy, Kaisa Kettunen, Ravindra Daddali, Mikko Seppänen, Markku Vänttinen, Timi Martelius, Juha Grönholm, Matilde Peri, Chiara Azzari, Silvia Ricci, Samar Ojaimi, Emily S. J. Edwards, Menno C. van Zelm, Jinqiao Sun, Hassan Abolhassani, Qiang Pan-Hammarström, Hakon Hakonarson, Daniel Mayr, Kaan Boztug, Bertrand Boisson, Jean-Laurent Casanova, Carole Le Coz, Gregory M. K. Poon, Neil Romberg

Blood (2025) 145 (22): 2549–2560.

https://doi.org/10.1182/blood.2024026683

Published: 2025

Includes: Supplemental data

Journal Articles

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Grace Egan, Sarah K. Tasian

Blood (2025) 145 (22): 2574–2586.

https://doi.org/10.1182/blood.2024026598

Published: 2025

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial

Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stüssi, Gisela Müller, Nathan Cantoni, Richard Cathomas, Ulrich Mey, Anouk Widmer, Thorsten Zenz, Michael Gregor, Dominik Heim, Martin Andres, Rudolf Benz, Davide Rossi

Blood (2025) 145 (22): 2587–2598.

https://doi.org/10.1182/blood.2024026879

Published: 2025

Includes: Supplemental data

Journal Articles

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Blood (2025) 145 (22): 2599–2613.

https://doi.org/10.1182/blood.2024025440

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Blood (2025) 145 (22): 2614–2629.

https://doi.org/10.1182/blood.2024024781

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Yakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, Shannon Martin, Sarah Bird, Yigen Li, Brian Walker, John Caldwell, Yann-Vaï Le Bihan, Charlotte Pawlyn

Blood (2025) 145 (22): 2630–2644.

https://doi.org/10.1182/blood.2024025861

Published: 2025

Includes: Supplemental data

Journal Articles

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

Yanna Ding, Kikkeri N. Naresh

Blood (2025) 145 (22): 2672.

https://doi.org/10.1182/blood.2025028556

Published: 2025

Journal Articles

SPI-ing on human B-cell development

Stuart G. Tangye

Blood (2025) 145 (22): 2535–2536.

https://doi.org/10.1182/blood.2025028405

Published: 2025

Journal Articles

Guidance on the interpretation of CRBN mutations in myeloma

K. Martin Kortüm, Hermann Einsele

Blood (2025) 145 (22): 2542.

https://doi.org/10.1182/blood.2024028272

Published: 2025

Journal Articles

HLA antibodies delay platelet recovery after gene therapy

Ashish O. Gupta, Akshay Sharma

Blood (2025) 145 (22): 2546–2547.

https://doi.org/10.1182/blood.2025028995

Published: 2025

Journal Articles

I+Ve got a question: how long should we treat relapsed CLL?

Moritz Fürstenau

Blood (2025) 145 (22): 2536–2538.

https://doi.org/10.1182/blood.2025028679

Published: 2025

Journal Articles

“Scotty, we need more power!”

Kelvin Lee

Blood (2025) 145 (22): 2540–2541.

https://doi.org/10.1182/blood.2025028349

Published: 2025

Journal Articles

Are you ready for it? VEN-HMA for younger patients with AML

Tara L. Lin

Blood (2025) 145 (22): 2543–2544.

https://doi.org/10.1182/blood.2025028825

Published: 2025

Journal Articles

It’s high TIM-3 for armored CAR-T therapy for B-ALL

Alexandros Rampotas, Claire Roddie

Blood (2025) 145 (22): 2538–2540.

https://doi.org/10.1182/blood.2025028491

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia

Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers

Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

SPI-ing on human B-cell development

Guidance on the interpretation of CRBN mutations in myeloma

HLA antibodies delay platelet recovery after gene therapy

I+Ve got a question: how long should we treat relapsed CLL?

“Scotty, we need more power!”

Are you ready for it? VEN-HMA for younger patients with AML

It’s high TIM-3 for armored CAR-T therapy for B-ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only